Literature DB >> 22708712

N-acetylcysteine use for amelioration of aminoglycoside-induced ototoxicity in dialysis patients.

Leonid Feldman, Richard A Sherman, Joshua Weissgarten.   

Abstract

Use of aminoglycoside antibiotics is associated with significant ototoxicity, especially on patients with decreased renal function. The risk of aminoglycoside ototoxicity may approach 60%. Oxidative stress has been suggested as a general mechanism of aminoglycoside ototoxicity and is prevalent in dialysis population. N-acetylcysteine (NAC) is an effective antioxidant and has been safely used in dialysis patients. New experimental and clinical data, explored in this review, provide a good case to recommend NAC administration to all dialysis patients, receiving aminoglycosides.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22708712     DOI: 10.1111/j.1525-139X.2012.01090.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  4 in total

Review 1.  Otoprotectants: From Research to Clinical Application.

Authors:  Colleen G Le Prell
Journal:  Semin Hear       Date:  2019-04-26

2.  When Proteins Start to Make Sense: Fine-tuning Aminoglycosides for PTC Suppression Therapy.

Authors:  Moran Shalev; Timor Baasov
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

3.  Preventing amikacin related ototoxicity with N-acetylcysteine in patients undergoing peritoneal dialysis.

Authors:  Ismail Kocyigit; Alperen Vural; Aydin Unal; Murat Hayri Sipahioglu; Hasan Esat Yucel; Samet Aydemir; Cevat Yazici; M İlhan Sahin; Oktay Oymak; Bulent Tokgoz
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-07-30       Impact factor: 2.503

4.  Toll-like Receptor 4 Signaling and Downstream Neutrophilic Inflammation Mediate Endotoxemia-Enhanced Blood-Labyrinth Barrier Trafficking.

Authors:  Zachary D Urdang; Jessica L Bills; David Y Cahana; Leslie L Muldoon; Edward A Neuwelt
Journal:  Otol Neurotol       Date:  2020-01       Impact factor: 2.619

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.